RxDoctor Payments Data

Ismael Rodriguez Rivera, MD

Internal Medicine · Bayamon, PRNPI 1487620340

Payments from drug & device makers

$679in general payments, 2019–2025

Across 20 payments — averaging $33.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$223
  • Johnson & Johnson$163
  • Boston Scientific$83
  • Lilly USA, LLC$78
  • Boehringer Ingelheim$67
  • Pfizer$35
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$679 in reported general payments places this provider in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$16,553
Medicare patients
19
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$118,444
JanuviaSitagliptin Phosphate70$96,270
FarxigaDapagliflozin Propanediol71$84,929
XareltoRivaroxaban54$65,906
JardianceEmpagliflozin38$53,379
SynthroidLevothyroxine Sodium272$29,114
LantusInsulin Glargine,hum.Rec.Anlog100$20,032
EntrestoSacubitril/Valsartan19$16,279
SynjardyEmpagliflozin/Metformin Hcl12$12,402
TrulicityDulaglutide12$11,913
BrilintaTicagrelor13$10,978
HumalogInsulin Lispro68$9,904
Xigduo XrDapaglifloz Propaned/Metformin13$9,596
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,712
Atrovent HfaIpratropium Bromide16$8,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$118,444108 claims
AstraZenecaFarxiga, Brilinta$223$95,90784 claims
Johnson & JohnsonXarelto$163$65,90654 claims
Boehringer IngelheimJardiance, Synjardy$67$65,78150 claims
Lilly USA, LLCTrulicity, Humalog, Humalog Mix 75-25, Humulin 70-30$78$27,544104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →